Market of Paclitaxel Injection in China
Nowadays, paclitaxel injection has been widely used to cure cancers like non-small cell lung cancer, breast cancer, and ovarian cancer, etc. Besides, paclitaxel injection has become one of the best selling anticancer drugs in the world. The paclitaxel injection production values had reached USD67.21 million for China in 2009, accounting for 10% of total in world. China has become one of the most important consumption markets in the world.
Chinese paclitaxel injection industry has witnessed significant development from 2005~2009. On the one hands, since 2005, China’s government has issued a series of policies related to China’s pharmaceutical industry like healthcare reform. What they effect the paclitaxel injection industry? On the other hand, paclitaxel injection has become the second largest market share in natural anticancer drugs in China, thanks to its good clinical effect and less side effect. What is the current production and consumption situation in China?
For China paclitaxel injection manufacturers, active pharmaceutical ingredient (paclitaxel APIs) plays an important role for them expend. Owing to the forbidden for the develop of natural yew and the development for planting yew, price of APIs has declined gradually, thus pushing down the price of paclitaxel injection price and get less profit. Besides, by the end of Jun. 2010, Chinese government has adjusted export tax rebate rate of paclitaxel injection. How the paclitaxel APIs and paclitaxel injection manufactures replied for this change? In 2009, Sichuan Jiufeng Pharmaceutical Nowadays, paclitaxel injection has been widely used to cure cancers like non-small cell lung cancer, breast cancer, and ovarian cancer, etc. Besides, paclitaxel injection has become one of the best selling anticancer drugs in the world. The paclitaxel injection production values had reached USD67.21 million for China in 2009, accounting for 10% of total in world. China has become one of the most important consumption markets in the world.
Chinese paclitaxel injection industry has witnessed significant development from 2005~2009. On the one hands, since 2005, China’s government has issued a series of policies related to China’s pharmaceutical industry like healthcare reform. How do they influence the paclitaxel injection industry? On the other hand, paclitaxel injection has enjoyed the second largest market share in natural anticancer drugs in China, thanks to its good clinical effect and less side effect. What is the current production and consumption situation in China?
For China paclitaxel injection manufacturers, active pharmaceutical ingredient (paclitaxel APIs) plays an important role for them expend. Owing to the increasing cultivated planting yew, price of APIs has declined gradually, thus pushing down the price of paclitaxel injection price. Besides, by the end of Jun. 2010, Chinese government has adjusted export tax rebate rate of paclitaxel injection. How did the paclitaxel APIs and paclitaxel injection manufacturers respond to this change? In 2009, Sichuan Jiufeng Pharmaceutical Co., Ltd. (Sichuan Jiufeng), the largest producer of paclitaxel injection in China, has increased its output of paclitaxel injection greatly because of the great demand, and then what is the performance of Sichuan Jiufeng in 2010?
What’s more, paclitaxel injection has to get into hospitals through the pharmaceutical distribution companies and medicine bidding and purchasing platforms. How do the pharmaceutical distribution companies distribute the paclitaxel injection, and how does the medicine bidding and purchase platforms for paclitaxel injection are operated?
Besides the aspects mentioned above, what is the production distribution of paclitaxel APIs? What is the development trend of China’s paclitaxel injection? CCM has carried out in-depth research and analysis on each active producer, as well as the whole industry to figure out these questions.
In this report, you can obtain info about:
Chinese paclitaxel injection industry has witnessed significant development from 2005~2009. On the one hands, since 2005, China’s government has issued a series of policies related to China’s pharmaceutical industry like healthcare reform. What they effect the paclitaxel injection industry? On the other hand, paclitaxel injection has become the second largest market share in natural anticancer drugs in China, thanks to its good clinical effect and less side effect. What is the current production and consumption situation in China?
For China paclitaxel injection manufacturers, active pharmaceutical ingredient (paclitaxel APIs) plays an important role for them expend. Owing to the forbidden for the develop of natural yew and the development for planting yew, price of APIs has declined gradually, thus pushing down the price of paclitaxel injection price and get less profit. Besides, by the end of Jun. 2010, Chinese government has adjusted export tax rebate rate of paclitaxel injection. How the paclitaxel APIs and paclitaxel injection manufactures replied for this change? In 2009, Sichuan Jiufeng Pharmaceutical Nowadays, paclitaxel injection has been widely used to cure cancers like non-small cell lung cancer, breast cancer, and ovarian cancer, etc. Besides, paclitaxel injection has become one of the best selling anticancer drugs in the world. The paclitaxel injection production values had reached USD67.21 million for China in 2009, accounting for 10% of total in world. China has become one of the most important consumption markets in the world.
Chinese paclitaxel injection industry has witnessed significant development from 2005~2009. On the one hands, since 2005, China’s government has issued a series of policies related to China’s pharmaceutical industry like healthcare reform. How do they influence the paclitaxel injection industry? On the other hand, paclitaxel injection has enjoyed the second largest market share in natural anticancer drugs in China, thanks to its good clinical effect and less side effect. What is the current production and consumption situation in China?
For China paclitaxel injection manufacturers, active pharmaceutical ingredient (paclitaxel APIs) plays an important role for them expend. Owing to the increasing cultivated planting yew, price of APIs has declined gradually, thus pushing down the price of paclitaxel injection price. Besides, by the end of Jun. 2010, Chinese government has adjusted export tax rebate rate of paclitaxel injection. How did the paclitaxel APIs and paclitaxel injection manufacturers respond to this change? In 2009, Sichuan Jiufeng Pharmaceutical Co., Ltd. (Sichuan Jiufeng), the largest producer of paclitaxel injection in China, has increased its output of paclitaxel injection greatly because of the great demand, and then what is the performance of Sichuan Jiufeng in 2010?
What’s more, paclitaxel injection has to get into hospitals through the pharmaceutical distribution companies and medicine bidding and purchasing platforms. How do the pharmaceutical distribution companies distribute the paclitaxel injection, and how does the medicine bidding and purchase platforms for paclitaxel injection are operated?
Besides the aspects mentioned above, what is the production distribution of paclitaxel APIs? What is the development trend of China’s paclitaxel injection? CCM has carried out in-depth research and analysis on each active producer, as well as the whole industry to figure out these questions.
In this report, you can obtain info about:
- Production distribution of paclitaxel APIs
- General situation of paclitaxel injection production and its manufacturers
- Top 2 pharmaceutical distribution companies in China
- Medicine bidding and purchasing platforms
- Import and export paclitaxel injection analysis, as well as paclitaxel APIs export analysis
- Consumption situation of paclitaxel injection
- Government policy for paclitaxel injection and quality standards of paclitaxel injection
- circulation model of paclitaxel injection in China
Executive summary
I DEVELOPMENT OF POLICY ENVIRONMENT FOR PACLITAXEL INJECTION IN CHINA
I-1 Regulation in GMP about paclitaxel injection
I-2 Regulation about paclitaxel injection in CP 2000
II PRODUCTION OF PACLITAXEL INJECTION IN CHINA
II-1 Production data from 2005 to 2009
II-2 Regional distribution of paclitaxel injection production
II-3 Summary of paclitaxel injection manufacturers in China, 2008&2009
II-4 Competition analysis of paclitaxel injection producers
III PRODUCTION OF PACLITAXEL APIS IN CHINA
IV CHINA’S PACLITAXEL INJECTION DISTRIBUTION MODEL
IV-1 Pharmaceutical distribution business in China
IV-1.1 Development history of pharmaceutical distribution business in China
IV-1.2 China’s major regional market share of pharmaceutical distribution business
IV-1.3 Sales value and concentration of pharmaceutical distribution business in China
IV-2 Introduce distribution of paclitaxel injection with Chinese characteristic
V CHINA’S MEDICINE BIDDING AND PURCHASING PLATFORM
V-1 Background of medicine bidding and purchasing platform
V-2 Flow chart of medicine bidding and purchasing platform
V-3 Top two pharmaceutical distribution companies
VI CONSUMPTION OF PACLITAXEL INJECTION IN CHINA
VI-1 Overview of anticancer drugs in China
VI-1.1 Consumption situation of natural anticancer drugs
VI-2 Consumption situation of paclitaxel injection
VI-2.1 Consumption in end-user sectors
VI-2.1.1 NSCLC
VI-2.1.2 Breast cancer
VI-2.1.3 Ovarian cancer
VI-2.2 Distribution of paclitaxel injection consumption in top five provinces
VI-3 Consumption potential analysis of paclitaxel injection in next 5 years
VI-3.1 Influencing factors for consumption
VI-3.2 Forecast consumption of paclitaxel injection in China, 2010-2015
VII IMPORT AND EXPORT SITUATION IN 2009
VII-1 Import and export situation for paclitaxel injection
VII-2 Export situation for paclitaxel APIs
VIII RESOURCE OF YEW IN CHINA
IX PROFILE OF MAJOR MANUFACTURERS OF PACLITAXEL INJECTION IN CHINA
LISTS OF TABELS
Table I-1 Regulations involving paclitaxel and its related products
Table I-2 Paclitaxel export tax rebate, 2005 to now
Table I-1.1Standard of purified water in China’s GMP
Table I-1.2 Quality standard of purified water
Table I-1.3 Standard of air cleanliness in China’s GMP
Table I-2.1 CP 2000 of paclitaxel injection of China
Table II-3.1 Active paclitaxel injection manufacturers in China, 2010
Table II-3.1 Active paclitaxel injection manufacturers situation in China, 2010
Table II-3.2 Product situation of active paclitaxel injection manufacturers in China, 2010
Table IV-1.3.1Sales value of pharmaceutical distribution companies in China, 2003-2009
Table VI-1.1 Market share of anticancer drugs in China, 2005-2009
Table VI-1.1.1 Sales value and market share of natural anticancer preparations in China, 2009
Table VI-2.1 Consumption volume of paclitaxel injection in China, 2005-2009
Table VI-2.2 Sales value and growth rate of paclitaxel injection in China, 2005-2009
Table VI-2.1.1.1 Number and growth rate of NSCLC patients in China, 2005-2009
Table VI-2.1.1.2 Consumption volume and growth rate of paclitaxel injection for NSCLC in China, 2005-2009
Table VI-2.1.2.1 Number and growth rate of breast cancer patients in China, 2005-2009
Table VI-2.1.2.2 Consumption volume and growth rate of paclitaxel injection for breast cancer in China, 2005-2009
Table VI-2.1.3.1 Number and growth rate of ovarian cancer patients in China, 2005-2009
Table VI-2.1.3.2 Consumption volume and growth rate of paclitaxel injection for ovarian cancer in China, 2005-2009
Table VI-2.2.1 Sales value and market share of paclitaxel injection in top five provinces in China, 2009
Table VII-1.1 Paclitaxel injection import situation in China, 2009
Table VII-1.2 Paclitaxel injection export situation in China, 2009
Table VII-2.1 Monthly export value of paclitaxel APIs in China, 2009
Table VII-2.2 Major export destinations of paclitaxel APIs from China, 2009
Table VII-2.3 Major exporters of paclitaxel APIs in China, 2009
Table VIII-1 Yew planting distribution in China, 2007-2009, strains
Table VIII-2 Cultivated yew planting distribution in China, 2007-2009, strains
LIST OF FIGURERS
Figure II-1.1 Production value of paclitaxel injection in China, 2005-2009
Figure II-2.1 Production value distribution of paclitaxel injection in China, 2009, USD
Figure II-2.2 Number of paclitaxel injection manufacturers in different provinces, 2009
Figure II-2.3 Production value structure of paclitaxel injection in China, 2009
Figure III-1.1 Production value of paclitaxel APIs in China, 2005-2009
Figure III-2.1 Production value distribution of paclitaxel APIs in China, 2009, USD
Figure III-2.2 Number of paclitaxel injection manufacturers in different provinces, 2009
Figure III-2.3 Production value structure of paclitaxel APIs in China, 2009
Figure IV-1 Situation of pharmaceutical distribution
Figure IV-1.1.1 Development of pharmaceutical distribution business in China
Figure IV-1.2.1 Geographical distribution of pharmaceutical distribution business by sales value in China, 2009
Figure IV-1.2.2 Market share of pharmaceutical distribution business in China by sales value, 2009
Figure IV-1.3.1 Sales value and market share of top 3 pharmaceutical distribution companies in China, 2003-2009
Figure IV-2.1 Circulation of paclitaxel injection with Chinese characteristic
Figure V-2.1 Flow chart of bidding and purchasing platform
Figure V-3.1 Main business lines of Sinopharm
Figure V-3.1 Main business lines of Shanghai Pharmaceutical
Figure VI-1.1 Sales value and growth rate of anticancer drugs in China, 2005-2009
Figure VI-2.1 Consumption pattern of paclitaxel injection by sales value in China, 2009
Figure VI-2.2 Consumption volume of paclitaxel injection in major segments in China, 2009
Figure VI-3.1.1 CAGR of consumption volume of paclitaxel injection in major end use segments, 2005-2009
Figure VI-3.2.1 Forecast on consumption volume of paclitaxel injection in China, 2010-2014
Figure VI-3.2.2 Forecast on consumption of paclitaxel injection in NSCLC in China, 2010-2014
Figure VI-3.2.3 Forecast on consumption of paclitaxel injection in breast cancer in China, 2010-2014
Figure VI-3.2.4 Forecast on consumption of paclitaxel injection in ovarian cancer in China, 2010-2014
Figure VIII-1 Number of cultivated yews in China, 2007-2009
Figure VIII-2 Geographical distribution of yew’s planting amount in China, 2009
COMPANIES MENTIONED
Sichuan Jiufeng Pharmaceutical Co., Ltd., Chongqing Taiji Industry (Group)Co., Ltd., Hainan Haiyao Joint-stock Co., Ltd., Hainan Quanxing Yaoye Co., Ltd., Zhejiang Hisun Pharmaceutical Co., Ltd.
I DEVELOPMENT OF POLICY ENVIRONMENT FOR PACLITAXEL INJECTION IN CHINA
I-1 Regulation in GMP about paclitaxel injection
I-2 Regulation about paclitaxel injection in CP 2000
II PRODUCTION OF PACLITAXEL INJECTION IN CHINA
II-1 Production data from 2005 to 2009
II-2 Regional distribution of paclitaxel injection production
II-3 Summary of paclitaxel injection manufacturers in China, 2008&2009
II-4 Competition analysis of paclitaxel injection producers
III PRODUCTION OF PACLITAXEL APIS IN CHINA
IV CHINA’S PACLITAXEL INJECTION DISTRIBUTION MODEL
IV-1 Pharmaceutical distribution business in China
IV-1.1 Development history of pharmaceutical distribution business in China
IV-1.2 China’s major regional market share of pharmaceutical distribution business
IV-1.3 Sales value and concentration of pharmaceutical distribution business in China
IV-2 Introduce distribution of paclitaxel injection with Chinese characteristic
V CHINA’S MEDICINE BIDDING AND PURCHASING PLATFORM
V-1 Background of medicine bidding and purchasing platform
V-2 Flow chart of medicine bidding and purchasing platform
V-3 Top two pharmaceutical distribution companies
VI CONSUMPTION OF PACLITAXEL INJECTION IN CHINA
VI-1 Overview of anticancer drugs in China
VI-1.1 Consumption situation of natural anticancer drugs
VI-2 Consumption situation of paclitaxel injection
VI-2.1 Consumption in end-user sectors
VI-2.1.1 NSCLC
VI-2.1.2 Breast cancer
VI-2.1.3 Ovarian cancer
VI-2.2 Distribution of paclitaxel injection consumption in top five provinces
VI-3 Consumption potential analysis of paclitaxel injection in next 5 years
VI-3.1 Influencing factors for consumption
VI-3.2 Forecast consumption of paclitaxel injection in China, 2010-2015
VII IMPORT AND EXPORT SITUATION IN 2009
VII-1 Import and export situation for paclitaxel injection
VII-2 Export situation for paclitaxel APIs
VIII RESOURCE OF YEW IN CHINA
IX PROFILE OF MAJOR MANUFACTURERS OF PACLITAXEL INJECTION IN CHINA
LISTS OF TABELS
Table I-1 Regulations involving paclitaxel and its related products
Table I-2 Paclitaxel export tax rebate, 2005 to now
Table I-1.1Standard of purified water in China’s GMP
Table I-1.2 Quality standard of purified water
Table I-1.3 Standard of air cleanliness in China’s GMP
Table I-2.1 CP 2000 of paclitaxel injection of China
Table II-3.1 Active paclitaxel injection manufacturers in China, 2010
Table II-3.1 Active paclitaxel injection manufacturers situation in China, 2010
Table II-3.2 Product situation of active paclitaxel injection manufacturers in China, 2010
Table IV-1.3.1Sales value of pharmaceutical distribution companies in China, 2003-2009
Table VI-1.1 Market share of anticancer drugs in China, 2005-2009
Table VI-1.1.1 Sales value and market share of natural anticancer preparations in China, 2009
Table VI-2.1 Consumption volume of paclitaxel injection in China, 2005-2009
Table VI-2.2 Sales value and growth rate of paclitaxel injection in China, 2005-2009
Table VI-2.1.1.1 Number and growth rate of NSCLC patients in China, 2005-2009
Table VI-2.1.1.2 Consumption volume and growth rate of paclitaxel injection for NSCLC in China, 2005-2009
Table VI-2.1.2.1 Number and growth rate of breast cancer patients in China, 2005-2009
Table VI-2.1.2.2 Consumption volume and growth rate of paclitaxel injection for breast cancer in China, 2005-2009
Table VI-2.1.3.1 Number and growth rate of ovarian cancer patients in China, 2005-2009
Table VI-2.1.3.2 Consumption volume and growth rate of paclitaxel injection for ovarian cancer in China, 2005-2009
Table VI-2.2.1 Sales value and market share of paclitaxel injection in top five provinces in China, 2009
Table VII-1.1 Paclitaxel injection import situation in China, 2009
Table VII-1.2 Paclitaxel injection export situation in China, 2009
Table VII-2.1 Monthly export value of paclitaxel APIs in China, 2009
Table VII-2.2 Major export destinations of paclitaxel APIs from China, 2009
Table VII-2.3 Major exporters of paclitaxel APIs in China, 2009
Table VIII-1 Yew planting distribution in China, 2007-2009, strains
Table VIII-2 Cultivated yew planting distribution in China, 2007-2009, strains
LIST OF FIGURERS
Figure II-1.1 Production value of paclitaxel injection in China, 2005-2009
Figure II-2.1 Production value distribution of paclitaxel injection in China, 2009, USD
Figure II-2.2 Number of paclitaxel injection manufacturers in different provinces, 2009
Figure II-2.3 Production value structure of paclitaxel injection in China, 2009
Figure III-1.1 Production value of paclitaxel APIs in China, 2005-2009
Figure III-2.1 Production value distribution of paclitaxel APIs in China, 2009, USD
Figure III-2.2 Number of paclitaxel injection manufacturers in different provinces, 2009
Figure III-2.3 Production value structure of paclitaxel APIs in China, 2009
Figure IV-1 Situation of pharmaceutical distribution
Figure IV-1.1.1 Development of pharmaceutical distribution business in China
Figure IV-1.2.1 Geographical distribution of pharmaceutical distribution business by sales value in China, 2009
Figure IV-1.2.2 Market share of pharmaceutical distribution business in China by sales value, 2009
Figure IV-1.3.1 Sales value and market share of top 3 pharmaceutical distribution companies in China, 2003-2009
Figure IV-2.1 Circulation of paclitaxel injection with Chinese characteristic
Figure V-2.1 Flow chart of bidding and purchasing platform
Figure V-3.1 Main business lines of Sinopharm
Figure V-3.1 Main business lines of Shanghai Pharmaceutical
Figure VI-1.1 Sales value and growth rate of anticancer drugs in China, 2005-2009
Figure VI-2.1 Consumption pattern of paclitaxel injection by sales value in China, 2009
Figure VI-2.2 Consumption volume of paclitaxel injection in major segments in China, 2009
Figure VI-3.1.1 CAGR of consumption volume of paclitaxel injection in major end use segments, 2005-2009
Figure VI-3.2.1 Forecast on consumption volume of paclitaxel injection in China, 2010-2014
Figure VI-3.2.2 Forecast on consumption of paclitaxel injection in NSCLC in China, 2010-2014
Figure VI-3.2.3 Forecast on consumption of paclitaxel injection in breast cancer in China, 2010-2014
Figure VI-3.2.4 Forecast on consumption of paclitaxel injection in ovarian cancer in China, 2010-2014
Figure VIII-1 Number of cultivated yews in China, 2007-2009
Figure VIII-2 Geographical distribution of yew’s planting amount in China, 2009
COMPANIES MENTIONED
Sichuan Jiufeng Pharmaceutical Co., Ltd., Chongqing Taiji Industry (Group)Co., Ltd., Hainan Haiyao Joint-stock Co., Ltd., Hainan Quanxing Yaoye Co., Ltd., Zhejiang Hisun Pharmaceutical Co., Ltd.
